The world may be a step closer to successfully treating obesity with psilocybin.
That’s because psilocybin activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.”
Even better, positive study results on obesity from NeonMind Biosciences (CSE: NEON) (OTC: NMDBF) show “psilocybin’s ability to modulate weight gain, which is absolutely critical for any drug candidate targeting obesity and weight loss,” said Robert Tessarolo, President & CEO of NeonMind. “In two separate rodent studies, we have shown that psilocybin has efficacy in modulating weight in both obese and normal subjects.”
Not only could that be game-changing news for NEON, but for other psychedelic companies, such as COMPASS Pathways (NASDAQ: CMPS), Cybin Inc. (NEO: CYBN) (NYSE: CYBN), Field Trip Health Ltd. (TSX: FTRP) (NASDAQ: FTRP), and Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED).